Human cells make new copies of their DNA billions of times each day, a crucial process upon which life itself depends. However, scientists do not fully understand how cells unzip the double-stranded DNA molecule before replicating both halves of it. New work at Rockefeller may help change that.

This Waters application note uses a panel of natural and synthetic opioid drugs to demonstrate the use of a systematic screening strategy for UPC2 method development.

Researchers from Bochum detect olfactory receptors in the skin. Receptor accelerates cell division and migration

As lab manager at the University of Pittsburgh Drug Discovery Institute (UPDDI), Celeste Reese and her team use high-content imaging strategies and work with many other labs both within the university and outside the university on a wide range of projects.

Automated solution unlocks the power of clinical data and accelerates LC-MS/MS workflows.

Possible pathway to adjustable filters, surfaces with variable mechanical response, or even new ways to deliver genes for biomedical applications.

Scientists at Thermo Fisher Scientific and BioAnalytix, Inc., of Cambridge, MA, are combining their expertise to develop advanced analytical profiling platforms and applications to characterize biologic and biosimilar drugs.

John Wiley & Sons, Inc., a global provider of knowledge and knowledge-enabled solutions that improve outcomes in research, professional practice, and education, announced today that it has acquired SimBioSys Inc., a provider of scientific software tools that facilitate the drug discovery process. Terms were not disclosed.

Neuroscience and cancer research added to statewide priorities: about $61 million awarded to URI since program began in 2001. Brown University, Rhode Island College, Providence College, Bryant University, Roger Williams University, Salve Regina University and CCRI are partners in RI-INBRE program.

Not when it comes to control of gene expression during dropsophila development.

Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) today announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases. The collaboration is built on an open-innovation model to bridge the gap between target discovery and pre-clinical drug development.